Hims & Hers Raises 2026 Revenue Forecast Amid Sales Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 hours ago
0mins
Should l Buy HIMS?
Source: Newsfilter
- Revenue Forecast Increase: Hims & Hers raised its 2026 revenue forecast to between $2.8 billion and $3 billion, up from the previous estimate of $2.7 billion to $2.9 billion, indicating strong confidence in the growth of its personalized healthcare offerings, which is expected to drive future performance.
- Partnership Restructuring: The company has partnered with Novo Nordisk to offer the weight-loss drug Wegovy on its platform, resolving a legal dispute that followed Hims' launch of a low-cost compounded alternative, which has since been discontinued, thereby restoring market trust and potentially enhancing product diversity and competitiveness.
- Quarterly Revenue Outlook: Hims expects second-quarter revenue to range from $680 million to $700 million, exceeding analysts' average estimate of $642.95 million, demonstrating strong demand and adaptability in the personalized healthcare sector.
- Stock Price Fluctuation: Despite the optimistic outlook, Hims' shares fell 6% to $27.20 in after-market trading, reflecting market concerns over short-term volatility, which may impact investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 29.140
Low
16.50
Averages
32.95
High
60.00
Current: 29.140
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong market demand and investment opportunities.
- Technology Innovation Showcase: VentriPoint will present its VMS+™ 4.0 platform at the AEPC annual meeting in Padua, Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI and significantly enhancing clinical diagnostic efficiency.
- International Expansion and Collaboration: VentriPoint has partnered with Lishman Global to submit VMS+™ 4.0 for approval to China's National Medical Products Administration, utilizing the expedited
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong demand for rapid and convenient healthcare solutions that create significant opportunities for companies like VentriPoint.
- Showcase Opportunity: VentriPoint will present its AI-powered VMS+™ 4.0 cardiac imaging platform at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology in Padua, Italy, expected to attract over 1,000 cardiology specialists from 32 countries, enhancing brand visibility and market penetration.
- Regulatory Expansion Progress: VentriPoint's strategic partner Lishman Global has formally submitted VMS+™ 4.0 for approval to China's National Medical Products Administration, leveraging the expedited
See More
Hims & Hers Health Adjusts 2026 Revenue Guidance Amid Q1 Earnings Miss
- Revenue Guidance Increase: Hims & Hers Health raised its 2026 revenue guidance to $2.8 billion - $3.0 billion from the previous forecast of $2.7 billion - $2.9 billion, indicating confidence in future growth despite missing Q1 earnings expectations.
- Q1 Earnings Miss: The company reported Q1 revenue of $608.1 million, a 4% increase year-over-year, but below Wall Street's expectation of $616.85 million, leading to a more than 15% drop in pre-market trading, reflecting investor concerns over performance.
- Analyst Rating Changes: Citi raised its price target for Hims from $24 to $28 while maintaining a 'Neutral' rating, and Needham increased its target from $30 to $35 with a 'Buy' rating, indicating confidence in the company's long-term growth potential.
- Retail Sentiment Shift: Despite the poor earnings report, retail sentiment on Stocktwits shifted from 'bearish' to 'neutral', with message volumes surging over 1,350% in 24 hours, reflecting divided opinions on Hims & Hers' future performance.
See More
Under Armour Reports Loss, Shares Drop 14%
- Earnings Loss: Under Armour reported a loss of 3 cents per share on revenue of $1.17 billion, significantly missing analyst expectations of a 2-cent loss and $1.68 billion in revenue, resulting in a 14% drop in stock price, highlighting the challenges the company faces in a competitive market.
- Acquisition Rejection: GameStop shares fell over 4% after eBay rejected its $56 billion takeover bid due to financing concerns, negatively impacting market confidence in GameStop's strategic direction.
- Strong Performance: On Holding's stock fell 5% in premarket trading despite reporting first-quarter earnings and revenue that exceeded analyst expectations, while reiterating its full-year net sales growth outlook, indicating resilience in its business model.
- Significant Stock Movement: Wendy's shares surged over 23% following reports that Trian Fund Management is raising funds for a bid to take the fast-food chain private, reflecting optimistic market sentiment regarding its privatization potential.
See More
Hims & Hers Reports Q1 Loss and Weak Guidance
- Financial Decline: Hims & Hers reported a net loss of $92 million in Q1, significantly worsening from a $50 million loss in the same period last year, indicating severe challenges in profitability.
- Adjusted EBITDA Drop: The company's adjusted EBITDA fell from $91 million last year to $44 million, reflecting declining operational efficiency and increasing cost pressures, which may undermine investor confidence moving forward.
- Weak Revenue Growth: Although revenue increased by 4% to $608 million, the average monthly revenue per subscriber decreased from $85 to $80, suggesting weakened consumer spending willingness that could impact long-term growth potential.
- Poor Outlook: Hims expects Q2 revenue between $680 million and $700 million, with a full-year forecast of up to $3 billion, but analysts believe this guidance falls short of market expectations, potentially leading to further stock price declines.
See More
Hims & Hers Health Misses Q1 Revenue Estimates, Shares Drop 15%
- Earnings Decline: Hims & Hers Health reported a loss of $0.40 per share for Q1, significantly missing analysts' expectations of a $0.04 profit, highlighting the financial strain during the company's transition period.
- Strategic Shift: The company pivoted towards branded GLP-1 weight-loss drugs during the quarter, which is expected to lead to profitability by 2027, but has pressured margins and domestic sales in the short term.
- Revenue Recognition Changes: The shift to shorter shipping schedules altered the timing of revenue recognition for some weight-loss products, impacting overall U.S. revenue performance and reflecting the challenges the company faces in adapting to the new market environment.
- Regulatory Risks: The FDA's restrictions on compounded versions of GLP-1 drugs and referral to the Department of Justice pose potential legal risks, with this news previously causing the company's shares to drop over 10% earlier this year.
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong market demand and investment opportunities.
- Technology Innovation Showcase: VentriPoint will present its VMS+™ 4.0 platform at the AEPC annual meeting in Padua, Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI and significantly enhancing clinical diagnostic efficiency.
- International Expansion and Collaboration: VentriPoint has partnered with Lishman Global to submit VMS+™ 4.0 for approval to China's National Medical Products Administration, utilizing the expedited
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong demand for rapid and convenient healthcare solutions that create significant opportunities for companies like VentriPoint.
- Showcase Opportunity: VentriPoint will present its AI-powered VMS+™ 4.0 cardiac imaging platform at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology in Padua, Italy, expected to attract over 1,000 cardiology specialists from 32 countries, enhancing brand visibility and market penetration.
- Regulatory Expansion Progress: VentriPoint's strategic partner Lishman Global has formally submitted VMS+™ 4.0 for approval to China's National Medical Products Administration, leveraging the expedited
See More
Hims & Hers Health Adjusts 2026 Revenue Guidance Amid Q1 Earnings Miss
- Revenue Guidance Increase: Hims & Hers Health raised its 2026 revenue guidance to $2.8 billion - $3.0 billion from the previous forecast of $2.7 billion - $2.9 billion, indicating confidence in future growth despite missing Q1 earnings expectations.
- Q1 Earnings Miss: The company reported Q1 revenue of $608.1 million, a 4% increase year-over-year, but below Wall Street's expectation of $616.85 million, leading to a more than 15% drop in pre-market trading, reflecting investor concerns over performance.
- Analyst Rating Changes: Citi raised its price target for Hims from $24 to $28 while maintaining a 'Neutral' rating, and Needham increased its target from $30 to $35 with a 'Buy' rating, indicating confidence in the company's long-term growth potential.
- Retail Sentiment Shift: Despite the poor earnings report, retail sentiment on Stocktwits shifted from 'bearish' to 'neutral', with message volumes surging over 1,350% in 24 hours, reflecting divided opinions on Hims & Hers' future performance.
See More
Under Armour Reports Loss, Shares Drop 14%
- Earnings Loss: Under Armour reported a loss of 3 cents per share on revenue of $1.17 billion, significantly missing analyst expectations of a 2-cent loss and $1.68 billion in revenue, resulting in a 14% drop in stock price, highlighting the challenges the company faces in a competitive market.
- Acquisition Rejection: GameStop shares fell over 4% after eBay rejected its $56 billion takeover bid due to financing concerns, negatively impacting market confidence in GameStop's strategic direction.
- Strong Performance: On Holding's stock fell 5% in premarket trading despite reporting first-quarter earnings and revenue that exceeded analyst expectations, while reiterating its full-year net sales growth outlook, indicating resilience in its business model.
- Significant Stock Movement: Wendy's shares surged over 23% following reports that Trian Fund Management is raising funds for a bid to take the fast-food chain private, reflecting optimistic market sentiment regarding its privatization potential.
See More
Hims & Hers Reports Q1 Loss and Weak Guidance
- Financial Decline: Hims & Hers reported a net loss of $92 million in Q1, significantly worsening from a $50 million loss in the same period last year, indicating severe challenges in profitability.
- Adjusted EBITDA Drop: The company's adjusted EBITDA fell from $91 million last year to $44 million, reflecting declining operational efficiency and increasing cost pressures, which may undermine investor confidence moving forward.
- Weak Revenue Growth: Although revenue increased by 4% to $608 million, the average monthly revenue per subscriber decreased from $85 to $80, suggesting weakened consumer spending willingness that could impact long-term growth potential.
- Poor Outlook: Hims expects Q2 revenue between $680 million and $700 million, with a full-year forecast of up to $3 billion, but analysts believe this guidance falls short of market expectations, potentially leading to further stock price declines.
See More
Hims & Hers Health Misses Q1 Revenue Estimates, Shares Drop 15%
- Earnings Decline: Hims & Hers Health reported a loss of $0.40 per share for Q1, significantly missing analysts' expectations of a $0.04 profit, highlighting the financial strain during the company's transition period.
- Strategic Shift: The company pivoted towards branded GLP-1 weight-loss drugs during the quarter, which is expected to lead to profitability by 2027, but has pressured margins and domestic sales in the short term.
- Revenue Recognition Changes: The shift to shorter shipping schedules altered the timing of revenue recognition for some weight-loss products, impacting overall U.S. revenue performance and reflecting the challenges the company faces in adapting to the new market environment.
- Regulatory Risks: The FDA's restrictions on compounded versions of GLP-1 drugs and referral to the Department of Justice pose potential legal risks, with this news previously causing the company's shares to drop over 10% earlier this year.
See More
